ANN ARBOR, Michigan, June 8, 2022 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, is sending senior members of the US management and research team to Vietnam to support multiple aspects of operations focused on manufacturing expansion and development of end markets.
This trip marks the return to normal travel and the participating management team members have a full agenda for this trip, following the lifting of travel restrictions.
Jon Rice, the company’s Chief Operations Officer, will travel throughout Vietnam to support Kraig Labs’ manufacturing expansion and commercialization on several fronts. Rice will meet with government officials in multiple provinces to discuss additional land for production and to gain support for further expanding the company’s spider silk technologies. He will hold a series of meetings with a contract side manufacturer with the aim of reaching an agreement for 3rd batch silk production. In previous discussions, this manufacturer already outlined a production scale-up plan to produce as much as 200 tons of silk per year. Another key purpose of this trip is to meet with Kraig Labs’ joint venture partners, PL Kings, and finalize plans for the first product launch under the Spydasilk brand. Rice plans to review textile mills under consideration to produce the first recombinant spider silk fabric under the Spydasilk brand.
“This is a timely and much-needed journey that will enable us to make the best decisions on the ground for Prodigy’s existing operations and the numerous potential expansion opportunities ahead. We are also excited to announce our teams in the US and Vietnam to meet evolving needs and personally address a diverse list of items that will set the direction of Kraig Labs’ next growth phase,” Rice said.
The company sends its senior scientist, Dr. Miller, to transfer additional process control technologies to the newly formed lab team of Prodigy Textiles, the company’s wholly owned Vietnamese subsidiary. dr. Miller will provide hands-on training for the implementation of several key manufacturing initiatives, including the installation of additional laboratory and manufacturing equipment and the transfer of additional R&D technology. dr. Miller will spend most of his time and effort working with new genetic screening protocols and monitoring current manufacturing processes.
“Dr. Miller’s focus will be on aligning the efforts of the Prodigy lab team members with his vision for the lab and his role in supporting production growth. This will ensure that lab team members are optimally trained and positioned to support the production team and cement. Prodigy as the best silkworm breeding facility in Vietnam,” concludes Rice.
To view the latest news from Kraig Labs and/or to sign up for company alerts, please visit: www.KraigLabs.com/news.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company, is a developer of genetically engineered spider silk-based fiber technologies.
Warning Regarding Forward-Looking Information
Statements in this press release about the company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made based on management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily materialize. These forward-looking statements can be identified generally by phrases such as “believes”, “plans”, “expects”, “anticipates”, “anticipates”, “estimates”, “hopes”, “if”, “develops” , “investigate”, “investigation”, “pilot”, “potential”, “could” or other words or phrases of similar meaning. Forward-looking statements include descriptions of the company’s strategy, prospects, objectives, plans, intentions and objectives. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or solicitation of an offer to purchase securities.
Ben Hansel, Hansel Capital, LLC